Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

ClinicalTrials.gov ID: NCT03717506

Public ClinicalTrials.gov record NCT03717506. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 11:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

Study identification

NCT ID
NCT03717506
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Balmoral Medical company
Industry
Enrollment
1,236 participants

Conditions and interventions

Conditions

Interventions

  • GDC 268 Lotion Drug
  • Clindamycin Phosphate Lotion 1% Drug
  • GDC Vehicle Lotion Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 40 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 9, 2018
Primary completion
Feb 16, 2020
Completion
Apr 15, 2020
Last update posted
May 3, 2021

2018 – 2020

United States locations

U.S. sites
34
U.S. states
19
U.S. cities
34
Facility City State ZIP Site status
Site 07 Fort Smith Arkansas 72916
Site 22 Rogers Arkansas 72758
Site 25 Fountain Valley California 92708
Site 33 Northridge California 91324
Site 30 San Diego California 92103
Site 44 Aventura Florida 33180
Site 36 Brandon Florida 33511
Site 45 DeLand Florida 32720
Site 41 Largo Florida 33770
Site 38 Miami Florida 33145
Site 35 Miami Lakes Florida 33014
Site 37 North Miami Beach Florida 33162
Site 26 St. Petersburg Florida 33709
Site 42 Tampa Florida 33609
Site 01 West Palm Beach Florida 33406
Site 10 Newnan Georgia 30263
Site 09 Boise Idaho 83704
Site 05 Rolling Meadows Illinois 60008
Site 02 Plainfield Indiana 46168
Site 27 Overland Park Kansas 66215
Site 28 Clarkston Michigan 48346
Site 24 Fridley Minnesota 55432
Site 49 Omaha Nebraska 68134
Site 06 High Point North Carolina 27262
Site 32 Raleigh North Carolina 27612
Site 19 Dublin Ohio 43016
Site 17 Gresham Oregon 97030
Site 34 Philadelphia Pennsylvania 19103
Site 20 Warwick Rhode Island 02886
Site 08 Anderson South Carolina 29621
Site 29 Chattanooga Tennessee 37421
Site 03 Murfreesboro Tennessee 37130
Site 04 Nashville Tennessee 37215
Site 43 Sugar Land Texas 77479

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03717506, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2021 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03717506 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →